Contact – +1-276-477-5910
 Email – [email protected]

Home >>

Healthcare and Social Assistance

>>

Global Monoclonal Antibodies mAbs Market


Global Monoclonal Antibodies (mAbs) Market 2020-2030 by Source (Human, Humanized, Chimeric, Murine), Category (Branded, Biosimilar), Production Type (In Vitro, In Vivo), Application (Cancer, Autoimmune, Inflammatory), End User, and Region: Trend Forecast and Growth Opportunity

Report code: SDMRHE1613137 | Industry: Healthcare and Social Assistance | Published On: 2022-01-07


Global monoclonal antibodies market will reach $329.6 billion by 2030, growing by 10.9% annually over 2020-2030, driven by the increasing incidences of new cancer cases and other diseases, growth in geriatric population, increasing pharmaceutical R&D spending, upsurge in healthcare expenditure, and the rising adoption of cost-efficient biosimilar monoclonal antibodies.
Highlighted with 83 tables and 84 figures, this 165-page report “Global Monoclonal Antibodies (mAbs) Market 2020-2030 by Source (Human, Humanized, Chimeric, Murine), Category (Branded, Biosimilar), Production Type (In Vitro, In Vivo), Application (Cancer, Autoimmune, Inflammatory), End User, and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global monoclonal antibodies market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19).
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global monoclonal antibodies market in every aspect of the classification from perspectives of Source, Category, Production Type, Application, End User, and Region.

Based on Source, the global market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• Human
• Humanized
• Chimeric
• Murine

Based on Category, the global market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• Branded mAbs
• Biosimilar mAbs

Based on Production Type, the global market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• In Vitro Production
• In Vivo Production

Based on Application, the global market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• Cancer
o Breast Cancer
o Colorectal Cancer
o Lung Cancer
o Ovarian Cancer
o Other Cancer Types
• Autoimmune Diseases
• Inflammatory Diseases
• Infectious Diseases
• Other Applications

By End User, the global market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• Hospitals
• Research Institutes
• Other End Users

Geographically, the following regions together with the listed national/local markets are fully investigated:
• North America (U.S., Canada, and Mexico)
• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
• South America (Brazil, Chile, Argentina, Rest of South America)
• MEA (UAE, Saudi Arabia, South Africa, Other Nations)
For each aforementioned region and country, detailed analysis and data for annual revenue ($ bn) are available for 2019-2030. The breakdown of all regional markets by country and split of key national markets by Source, Application, and End User over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Key Players (this may not be a complete list and extra companies can be added upon request):
Abbott Laboratories
AbbVie, Inc.
Amgen Inc.
AstraZeneca plc
Bayer AG
Bristol-Myers Squibb Company
Eli Lilly
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Johnson & Johnson
Merck & Co., Inc.
Mylan N.V
Norvatis AG
Pfizer
Sanofi S.A.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

1  Introduction 9
1.1  Industry  Definition  and  Research  Scope 9
1.1.1  Industry  Definition 9
1.1.2  Research  Scope 10
1.2  Research  Methodology 13
1.2.1  Overview  of  Market  Research  Methodology 13
1.2.2  Market  Assumption 14
1.2.3  Secondary  Data 14
1.2.4  Primary  Data 14
1.2.5  Data  Filtration  and  Model  Design 15
1.2.6  Market  Size/Share  Estimation 16
1.2.7  Research  Limitations 17
1.3  Executive  Summary 18
2  Market  Overview  and  Dynamics 21
2.1  Market  Size  and  Forecast 21
2.1.1  Impact  of  COVID-19  on  World  Economy 22
2.1.2  Impact  of  COVID-19  on  the  Market 25
2.2  Major  Growth  Drivers 27
2.3  Market  Restraints  and  Challenges 32
2.4  Emerging  Opportunities  and  Market  Trends 35
2.5  Porter’s  Fiver  Forces  Analysis 39
3  Segmentation  of  Global  Market  by  Source 43
3.1  Market  Overview  by  Source 43
3.2  Human 45
3.3  Humanized 46
3.4  Chimeric 47
3.5  Murine 48
4  Segmentation  of  Global  Market  by  Category 49
4.1  Market  Overview  by  Category 49
4.2  Branded  mAbs 51
4.3  Biosimilar  mAbs 52
5  Segmentation  of  Global  Market  by  Production  Type 53
5.1  Market  Overview  by  Production  Type 53
5.2  In  Vitro  Production 55
5.3  In  Vivo  Production 56
6  Segmentation  of  Global  Market  by  Application 57
6.1  Market  Overview  by  Application 57
6.2  Cancer 59
6.2.1  Breast  Cancer 61
6.2.2  Colorectal  Cancer 62
6.2.3  Lung  Cancer 63
6.2.4  Ovarian  Cancer 64
6.2.5  Other  Cancer  Types 65
6.3  Autoimmune  Diseases 66
6.4  Inflammatory  Diseases 67
6.5  Infectious  Diseases 68
6.6  Other  Applications 69
7  Segmentation  of  Global  Market  by  End  User 70
7.1  Market  Overview  by  End  User 70
7.2  Hospitals 72
7.3  Research  Institutes 73
7.4  Other  End  Users 74
8  Segmentation  of  Global  Market  by  Region 75
8.1  Geographic  Market  Overview  2019-2030 75
8.2  North  America  Market  2019-2030  by  Country 79
8.2.1  Overview  of  North  America  Market 79
8.2.2  U.S. 83
8.2.3  Canada 86
8.2.4  Mexico 88
8.3  European  Market  2019-2030  by  Country 90
8.3.1  Overview  of  European  Market 90
8.3.2  Germany 94
8.3.3  U.K. 96
8.3.4  France 98
8.3.5  Spain 100
8.3.6  Italy 102
8.3.7  Russia 104
8.3.8  Rest  of  European  Market 106
8.4  Asia-Pacific  Market  2019-2030  by  Country 108
8.4.1  Overview  of  Asia-Pacific  Market 108
8.4.2  Japan 112
8.4.3  China 115
8.4.4  Australia 117
8.4.5  India 119
8.4.6  South  Korea 121
8.4.7  Rest  of  APAC  Region 123
8.5  South  America  Market  2019-2030  by  Country 125
8.5.1  Argentina 128
8.5.2  Brazil 130
8.5.3  Chile 132
8.5.4  Rest  of  South  America  Market 134
8.6  MEA  Market  2019-2030  by  Country 135
8.6.1  UAE 138
8.6.2  Saudi  Arabia 140
8.6.3  South  Africa 142
8.6.4  Other  National  Markets 144
9  Competitive  Landscape 145
9.1  Overview  of  Key  Vendors 145
9.2  New  Product  Launch,  Partnership,  Investment,  and  M&A 148
9.3  Company  Profiles 149
Abbott  Laboratories 149
AbbVie,  Inc. 151
Amgen  Inc. 152
AstraZeneca  plc 153
Bayer  AG 154
Bristol-Myers  Squibb  Company 155
Eli  Lilly 156
F.  Hoffmann-La  Roche  Ltd. 157
GlaxoSmithKline  Plc 158
Johnson  &  Johnson 159
Merck  &  Co.,  Inc. 160
Mylan  N.V 161
Norvatis  AG 162
Pfizer 163
Sanofi  S.A. 164
RELATED  REPORTS 165
For more information, please contact [email protected]
 Feel free to contact us

 
Choose License Type
Select User Type


Report code




x

Use Code

SDMR20

Purchase any report

AVAIL FLAT DISCOUNT